Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.16/1743
Título: Membranoproliferative glomerulonephritis associated with type II cryoglobulinaemia in a renal transplant patient with hepatitis C
Autor: Bento, C.
Malheiro, J.
Almeida, M.
Martins, L.
Dias, L.
Vizcaíno, J.
Castro-Henriques, A.
Palavras-chave: Cryoglobulinaemia
hepatitis C
kidney transplant
membranoproliferative glomerulonephritis
rituximab
Data: 2014
Editora: Sociedade Portuguesa de Nefrologia
Citação: Port J Nephrol Hypert 2014; 28(2): 164-167
Resumo: The most common HCV-related nephropathy is membranoproliferative glomerulonephritis (MPGN), usually in the context of cryoglobulinaemia. The treatment of this entity is not consensual and represents a challenge to clinicians. We report a case of membranoproliferative glomerulonephritis associated with cryoglobulinaemia type II in a 46-year-old Caucasian male recipient of a deceased kidney transplant in 2010. His baseline serum creatinine (SCr) was 1.1 mg/dl. After three years post-transplantation, he presented with nephritic syndrome in association with renal function impairment (SCr – 2.1 mg/dl). The laboratory tests revealed positive rheumatoid factor, hypocomplementaemia and a positive cryocrit with type II cryoglobulinaemia. Antinuclear autoantibodies and anti-double stranded DNA antibodies were negative. Despite the presence of anti-HCV antibodies, the viral load remained undetectable. The allograft biopsy showed lesions compatible with membranoproliferative glomerulonephritis, with staining in the immunofluorescence for granular IgM and C3 and no C4d. He was treated with methylprednisolone pulses followed by oral prednisolone in association with rituximab. Two months after the last dose of rituximab, the SCr improved to 1.27 mg/dl, the proteinuria decreased and serum C3 levels normalized. Cryogloglobulins and rheumatoid factor became negative and HCV RNA remained undetectable. The patient was lost for follow-up. In our case, the treatment with rituximab resulted in a favourable outcome, although a longer follow-up period may be needed to evaluate the clinical response, since other studies reported high relapse rates.
Peer review: yes
URI: http://hdl.handle.net/10400.16/1743
Versão do Editor: http://www.spnefro.pt/RPNH/PDFs/n2_2014/artigo_11.pdf
Aparece nas colecções:SAP - Artigos publicados em revistas não indexadas na Medline
SNEF - Artigos publicados em revistas não indexadas na Medline

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Membranoproliferative.pdf275,61 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.